Optimal Treatment Duration of Pseudomonas aeruginosa Infections in Allogeneic Hematopoietic Cell Transplant Recipients | Zendy

Flaminia Olearo | Zendy; Ilona Kronig | Zendy; Stavroula MasouridiLevrat | Zendy; Yves Chalandon | Zendy; Nina Khanna | Zendy; Jakob Passweg | Zendy; Michael Medinger | Zendy; Nicolas J. Mueller | Zendy; Urs Schanz | Zendy; Christian van Delden | Zendy; Dionysios Neofytos | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Optimal Treatment Duration of Pseudomonas aeruginosa Infections in Allogeneic Hematopoietic Cell Transplant Recipients

Author(s) -

Flaminia Olearo,

Ilona Kronig,

Stavroula MasouridiLevrat,

Yves Chalandon,

Nina Khanna,

Jakob Passweg,

Michael Medinger,

Nicolas J. Mueller,

Urs Schanz,

Christian van Delden,

Dionysios Neofytos

Publication year - 2020

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofaa246

Subject(s) - medicine , pseudomonas aeruginosa , hematopoietic cell , haematopoiesis , hematopoietic stem cell transplantation , pathogenic organism , microbiology and biotechnology , immunology , transplantation , stem cell , bacteria , biology , genetics

In a large, multicenter, contemporary, 8-year, cohort study, one third of allogeneic-hematopoietic cell transplant (HCT) recipients with (PSA) infection developed a recurrent infection within 3 months. Antibiotic treatment duration of ≥14 days was the only significantly associated variable with reduced recurrence rates of PSA infections in allogeneic-HCT recipients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research